Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody - Test2 - elhamkhani - TriplyDB

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

http://www.wikidata.org/entity/Q28286616

about

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4 The amazing osteocyte Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Sclerostin Inhibition in the Management of Osteoporosis From disease to treatment: from rare skeletal disorders to treatments for osteoporosis Mechanism and Treatment Strategy of Osteoporosis after Transplantation Catabolic and anabolic actions of parathyroid hormone on the skeleton Impact of inflammation on the osteoblast in rheumatic diseases A review of denosumab for the treatment of osteoporosis The osteocyte as a therapeutic target in the treatment of osteoporosis Denosumab for the treatment of osteoporosis Osteocytes: master orchestrators of bone Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management Parathyroid Hormone Induces Bone Cell Motility and Loss of Mature Osteocyte Phenotype through L-Calcium Channel Dependent and Independent Mechanisms Bone anabolics in osteoporosis: Actuality and perspectives LRP5 and LRP6 in development and disease Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density WNT signaling in bone homeostasis and disease: from human mutations to treatments Regulation of Wnt/β-catenin signaling within and from osteocytes Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition Recent advances in the pathogenesis and treatment of osteoporosis The management of osteoporosis in children.Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway Investigational drugs for fracture healing: preclinical & clinical data.Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.Profile of romosozumab and its potential in the management of osteoporosis.Parathyroid hormone: anabolic and catabolic actions on the skeleton Bisphosphonate treatment for children with disabling conditions.Pharmacological management of osteogenesis.Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations Novel therapeutic targets in myeloma bone disease.Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics

P2860

Q24299076-85BCAECA-DFC6-4E53-92E2-713E19A901E8 Q24309550-D223598F-5259-481A-B9FC-1AF0AD59F441 Q24635849-768A5C97-C9C8-4148-BB16-6A1A716E8DC2 Q26744599-7F4FCDF6-8DEC-4329-BE75-CE7A976707E2 Q26750713-6B55CBAC-5384-4835-AA53-4604CCED9A49 Q26764854-753E8445-205C-44CC-80C9-D28318893A75 Q26798296-6813A036-A49A-404B-A3F6-D70A7F49842C Q26828873-D2BCF41A-3CBA-4688-A757-21615781A7B7 Q26829246-A8EF265F-1E62-4A0F-B607-9B3BC3701B5B Q27005894-8F3CF7AA-4685-4A8F-9C8E-BB6DE2260824 Q27009129-C8CA25D8-841A-4FE9-BA3E-87A242977948 Q27009275-D99601DB-95D2-47CB-8B18-9191E9D38A62 Q27022407-71FEC608-F14B-42DE-98F7-01EE05F09A4B Q27022580-14781924-ED8B-4DBC-9B16-9FEBCDA92569 Q27025982-1FC87211-02A8-461B-A4E9-EA8A24164BE2 Q27308118-D62431AA-87BB-4B7E-B79A-144E35E07843 Q27691122-67B6E36E-470B-4592-B2B3-F78AF9DF467E Q27692072-677978B0-25E5-48ED-B5CF-618539345E82 Q28115466-85EBC45A-005F-4B28-9D22-1E7104CC95CC Q28247445-ED18EEFF-0826-40A2-BEFE-7C4CB04E65A3 Q28285090-173903D7-3458-4707-8692-03AFDEFD9DF4 Q28286814-AA22F632-BEF6-473A-BE51-C8D21B0BBC1C Q28535490-61B091DB-118D-41BB-A8F9-E1C6FB3BCAC7 Q30248661-F3303392-F3B6-4691-9C9E-735608314DF8 Q30251490-999FC9E0-0C57-4D70-8BBF-CE520F113EEC Q30713102-9C271E1A-CE17-45B3-95BA-42C9D2EFC198 Q31032805-E3BCDE99-61A1-4493-A7A8-D6805711B96B Q31052456-6E3A380F-E282-49DC-9ADD-B60502C17149 Q33554916-12160415-7B63-431F-B295-8C81D8D81E31 Q33564617-93508F26-CAD6-4811-AF1D-2A12C8203C50 Q33570177-A4B75BDF-9CF1-4D4D-A5BB-164DB6DF10DD Q33596475-9A221210-6867-44C3-88D2-07F42659BA0E Q33609126-C43CB2D2-69FE-40FC-AC04-8CBDC378922F Q33680621-EDD99B63-C016-46BD-82A3-A80A196213D0 Q33729548-104195F7-A2F7-4473-B612-460467206F97 Q33835723-136E9A20-C5A9-4402-8DBC-D289E4101AF4 Q33847609-CE4AA7D5-1817-4E37-87D8-6F54131190C3 Q34025065-4169E5B9-2314-4D4C-80F9-CD9133F8F865 Q34036439-822A1515-DE6A-440F-BF32-A35D6915DD6B Q34038854-F1B7B2B0-EBAF-42AB-AF3A-B8F7EF7C3FA5

P2860

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

http://www.wikidata.org/entity/Q28286616

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@ast

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@en

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@nl

type

label

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@ast

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@en

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@nl

prefLabel

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@ast

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@en

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@nl

P1433

Q28286616-C73DC743-5102-406E-A531-0145EBB75F08

P1476

Q28286616-336411A8-F024-47AD-90F2-4D01F969E945

P2093

Q28286616-020E9F8D-E193-4D5D-9D0A-68956D554B83

Q28286616-58D3ADEE-ACCE-4AF5-AC38-4A7B88545E15

Q28286616-9D30B549-C2F4-4265-8BAC-85A969F356F6

Q28286616-A1EE15C2-5482-4C8A-9F3D-CD861C18E2BF

Q28286616-CEA5B9DE-2B93-46D3-A81C-1D8D91B6F069

P2860

Q28286616-16A895BB-166A-4966-B56F-EB8913DFDFCF

Q28286616-22C39031-6610-40A2-83EF-AE5147A5E810

Q28286616-23648486-F944-4E8F-8520-D8480C9C00E1

Q28286616-387E290F-F31F-4BFA-B902-9483032CD7CC

Q28286616-4237D7D0-064F-46EA-9225-03EF0EAA1560

Q28286616-527ED583-FFE9-43FA-91F8-B4CEAEDE0930

Q28286616-62ED7DD8-2340-49D1-9918-AC3CFE009225

Q28286616-665134C0-A64F-44C0-AA8B-B15587AC6D55

Q28286616-77CE4DD2-3DF1-4B6F-9381-B9BC4F736E58

Q28286616-7A415511-F7B8-4693-9769-A61AB41316AD

P304

Q28286616-70DE985D-4B20-4A30-ADE2-31181FAF7ED0

P31

Q28286616-AD1D1A31-E65E-47D3-B453-6B09C57E98A1

P3181

Q28286616-B5DDAF9E-735B-4430-8A91-606164FA9879

P356

Q28286616-4C2B0B3A-5D60-418D-8B29-25806E246558

P407

Q28286616-77957EC7-82C9-40D9-BB58-397492EB64AC

P433

Q28286616-6F2DB043-F2CB-4B87-A048-5ECDC794EED4

P478

Q28286616-431258AF-E764-494D-A87E-C575CF218FAE

P577

Q28286616-6BDC9BF6-76A7-43FA-8DF7-27F207199A27

P5875

Q28286616-CC691106-4910-4307-B269-D3FA926847B8

P698

Q28286616-DE8FD67C-C0BB-465E-891E-591888B19294

P921

Q28286616-7142D13A-971B-46D8-A0DB-F85A7204D896

Q28286616-97004DB4-A6CF-4011-8E7C-9678EE02FFFB

P3181

P356

P1433

Journal of Bone and Mineral Research

P1476

Single-dose, placebo-controlle ...... sclerostin monoclonal antibody

@en

P2093

Brian Stouch

http://www.w3.org/2001/XMLSchema#string

Desmond Padhi

http://www.w3.org/2001/XMLSchema#string

Edward Posvar

http://www.w3.org/2001/XMLSchema#string

Graham Jang

http://www.w3.org/2001/XMLSchema#string

Liang Fang

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

P304

19-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1230178

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/JBMR.173

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44890167

http://www.w3.org/2001/XMLSchema#string

P698

20593411

http://www.w3.org/2001/XMLSchema#string

P921